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Abstract
Background: Recent studies have found that p53 and its’ associated cell cycle pathways are major inhibitors of
human induced pluripotent stem (iPS) cell generation. In the same family as p53 is p73, which shares sequence
similarities with p53. However, p73 also has distinct properties of its own, such as two alternative promoters to
express transactivation of p73 (TAp73) and N terminal deleted p73 (DNp73). Functionally, TAp73 acts similarly to
p53 in tumor suppression. However, DNp73, on the other hand acts as an oncogene to suppress p53 and p73
induced apoptosis. Therefore, how can p73 have opposing roles in human iPS cell generation?
Results: Transcription factors, Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors) are used as basal conditions to
generate iPS cells. In addition, the factor of DNp73(actually alpha splicing DNp73, DNp73a) is used to generate iPS
cells. The experiment found that the addition of DNp73 gene increases human iPS cell generation efficiency by
12.6 folds in comparison to human fibroblast cells transduced with only the basal conditions. Also, iPS cells
generated with DNp73 expression are more resistant to in vitro and in vivo differentiation.
Conclusions: This study found DNp73, a family member of p53, is also involved in the human iPS cell generation.
Specifically, that the involvement of DNp73 generates iPS cells that are more resistant to in vitro and in vivo
differentiation. Therefore, this data may prove to be useful in future developmental studies and cancer researches.
Background
Human induced pluripotent stem cells hold great pro-
mise in regenerative medicine, disease modeling, and
drug discovery [1,2]. However, the iPS cell generation
efficiency is extremely low at around 1 from 10,000 par-
ental cells [1,2], limiting its’ use. Also, such a low effi-
ciency suggests that major factors in de-differentiation
or reprogramming have not been identified yet.
Recently, a series of breakthrough discoveries have
brought to attention that, blocking the important tumor
suppressor protein p53, and its downstream pathways,
dramatically improves generation efficiency of induced
pluripotent stem cells [3-7]. The data suggest that p53 is
a key link between cellular reprogramming and tumor
formation since it prevents differentiated cells from
transforming into pluripotent stem cells.
In 2005, we found that p53 induced differentiation of
mouse embryonic stem (ES) cells by inhibiting a core
transcription factor, Nanog, in the presence of stresses
[8]. Nanog is a key ES cell transcription factor; Loss of
Nanog expression led to rapid differentiation [9,10]. The
p53 protein directly binds to the Nanog promoter to
suppress its’ expression level and thereby initiate ES cell
differentiation into somatic like cells. Therefore, p53
acts as a transcription switch because it is able to inhibit
ES cells with genetic defects to self-renew causing them
to differentiate into non-stem cells, and execute high
efficient apoptosis [8,9].
Previous research by Yamanaka and group reported
that up to 10% transduction of p53 mouse embryonic
fibroblasts (mEF) can be generatedinto iPS cells [3]. P53
gene deletion enhances efficiency about 1000-fold. In
addition, p53 activity can also provide sufficient condi-
tions to turn the terminal differentiated T lymphocytes
into iPS cells. Another research team found that repla-
cing transcription factors cMYC and KLF4 with p53
gene knockout, was enough to generate iPS cells [4].
Thus, P53 is the major inhibitor of iPS cell generation.
P73 is a p53 family member with similar sequence and
function as p53 [11]. However, previous studies showed
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other conditions. In addition, the p73 gene expresses
products with two alternative promoters, transactivation
p73 (TAp73 and N terminal deleted p73 (DNp73)
[11,12]. TAp73 functions similar to p53 in that it may
play a role in cancer suppression. Conversely, DNp73
f u n c t i o n sa sa no n c o g e n eb y inhibiting both p73- and
p53-induced apoptosis [13].
Therefore, how can there be opposing roles in human
iPS cell generation? We propose that p73 might be
involved in human reprogramming. We further suggest
that, DNp73 might increase the efficiency of human iPS
cell generation.
Results
DNp73 overexpression enhanced human iPS cell
generation
As control treatments, we applied conditions that were
reported before by traditional four transcription factors
[OCT4, SOX2, cMyc, and Klf4, referred 4TF [1,11,14].
To see if the DNp73 enhances human iPS cell genera-
tion, DNp73 was cloned by PCR from cDNA and
inserted into the pMXs vector. Next, the newly gener-
ated vector was transduced with 4TF together into
human fibroblast cell BJ.
At day 30, in the traditional 4TF conditions, the effi-
ciency of iPS cell generation was at 1 from 10,000 levels
from human fibroblasts BJ, similar to previous reports
[1,2].
In sharp contrast, at day 21 after infection, the fully
reprogrammed ES like iPS cell colonies generated in
4TF plus DNp73 infected cultures yielded 21.0 colonies
versus control cultures which yielded 1.67 colonies per
10,000 parental cell seeded. This translates into a 12.6
fold enhancement by the reprogrammed ES like iPS
cells (Figure 1a, b, c). Furthermore, the ES like iPS cells
tested positive for human ES cell marker Nanog, deter-
mined by using TRA-1-81, which dramatically increased
Nanog gene expression in the culture mixture (Figure
1d, e), suggesting the cell cultures were strongly
enhanced toward iPS cell generation. The expression of
DNp73 gene enhanced fibroblast reprogramming sug-
gest that p73 may also play an important role in human
iPS cell generation, at least when transduced with tradi-
tional 4TF in human fibroblast cells by the traditional
human iPS cell generation method.
The human iPS cells were identified with self-renewal and
pluripotency
To test the pluripotent stem cell property of self-
renewal, the iPSC cells were passaged. After 12 pas-
sages, the iPS cells did not have morphological
changes when their properties were characterized.
Cell morphology was examined with ALP staining
(Figure 2a) and real time PCR gene expression. Real
time PCR results showed that these cells are similar
to human embryonic stem cells huES9, which have
the same or similar gene expression levels (Figure
2b). The results show that immunohistochemical
staining results of the iPS cells were similar to human
ES cells, with strong expressed OCT3/4 and Nanog
(Figure 2c, d, e, f).
Figure 1 Additional DNp73 transduction increase human iPSC
generation efficiency and kinetics at day 21. Timeline for human
iPSC induction combined dnp73 withtraditional 4TF. Treatment with
additional factor dnp73: culture plate had colony growth at d21
with Nanog expression and at d30 with the traditional iPS cells. a.
Culture derived from 4 TF only, had only a few colonies stained by
ALP+. b. While, in the culture derived from transduction of 4TF plus
DNp73, many colonies appeared when stained with ALP positive at
day 21. c. At day 30, large colonies seen with Nanog expression,
with approx. 20 fold increase by comparison between 4TF only and
4TF plus DNp73. d. significant enhancement of gene expression
oct4 (/) and Nanog (/) by Qautitative PCR detection of the cultures
at d30.
Lin et al. BMC Cell Biology 2012, 13:9
http://www.biomedcentral.com/1471-2121/13/9
Page 2 of 7To test in vitro differentiation potential, an embryonic
body mediated differentiation of iPS cells experimental
methods was applied. The results showed that these iPS
cells can be differentiated into derivatives of all three
germ layers, including mesoderm, endoderm and ecto-
derm (Figure 3). These cells are Brachyury positive, a
conserved role in mesoderm differentiation, and estab-
lish the embryonic mesodermal progenitor (Figure 3a-c).
The endoderm cells are marked by early expression of
the gene Pdx1 (Figure 3d-f). The immunocytochemistry
also showed cells positive for TUJ1 stained ectoderm
cells (Figure 3g-i).
To test pluripotency in vivo, human iPS cells were
transplanted by injection into the kidney of immunode-
ficiency (SCID) mice. After 6 weeks, histological sections
from teratomas generated in nude mice from iPS cells
consisted of tissues from all three germ layers stained
with hematoxylin and eosin (HE). Using 400× magnifi-
cation, three germ layers of cell lines were identified,
including mesoderm (cartilage) (Figure 3j), endoderm
Figure 2 Characterization of the passaged culture (p5) of the
additional dnp73 transduced human iPS cell. a. ALP staining of
the passaged colonies. b. Real time results show the gene
expression levelthat iPSC are similar to those in human ES cell. c. A
typical colony of passaged cell stainied with Oct4 antibody. d.
Stained with Nanog. e. DAPI cell nuclear staining. f. Merged triple
stainings of c d & e.
Figure 3 In vitro and in vivo differentiation of iPSCs generated
with 4TF plus DNp73. In vitro differentiation through embryoid
bodies, subsequently differentiate to mesoderm (a. bracchyury
staining, b. DAPI staining, c. merged), to endoderm (d. PDX1, e.
DAPI, f. merged), and ectoderm (g. Tuj1 staining, h. DAPI, and i.
merged). Histological sections from teratomas generated in nude
mice from iPSCs consist of tissues from all three germ layers stained
with hematoxylin and eosin (HE). Magnification folds 400×, J.
mesoderm (1. cartilage); k. endoderm (2. goblet cells); l. ectoderm (3.
neural epithelium); m. non-differentiation cells.
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(Figure 3l).
Resistance from differentiation cues was found in the
human iPS cells generated with DNP73
We observed iPS cell differentiation under microscope at
objective fields of 100× or 200×. Each sample of teratoma
was randomly observed for 10 microscopic fields. We
found that the iPS cell with DNp73 was resistant to in vivo
differentiation (teratoma), which contained all undifferen-
tiated cells in some microscopic fields (Figure 3m). We
compared the 2 types of teratoma by randomly picking 10
microscopic fields. In control cells, all (100%) the micro-
scopic fields had evidence of specific cells. However, the
DNp73 derived teratoma had fewer differentiated cells,
with only 20% of the fields containing all non-specific cells
(Table 1)and the majority of the sections contained non-
differentiated cells, 30-100% ratio. On the contrary, less
than 30% non-specific cells were found in the teratoma
derived from control iPSC (Table 1).
In vitro differentiation demonstrated a strong differ-
ence between the cells derived from 4TF only iPS cells
and those derived from iPS cells with additionally trans-
duced DNp73. Neuronal marker cells stained by TUJ 1
antibody were observed from all 10 of the tested fields
in 4TF transduced cells. However, 2 out of 10 fields
stained negative in those derived from iPS cell with 4
TF plus DNp73. Furthermore, we did not find any typi-
cal bipolar TUJ1 strong expression neuronal cells. The
data suggest that the DNp73 iPS cells are strongly resis-
tant to neuronal differentiation.
DNp73 increased ES cell core transcription factor Nanog
expression
To find out how the p73 gene can improve the effi-
ciency of iPS cells, we examined luciferase expression in
mouse ES cells (Figure 4). Using our previous experi-
mental system [8], the exogenous expression of p53 in
mouse ES cells resulted in significant inhibition of the
Nanog promoter-driven luciferase gene expression. We
carried out TAp73 expression in the same cells, and
found results similar to those from p53 transfected cells
(Figure 4). However, in sharp contrast, DNp73 signifi-
cantly increased Nanog gene promoter-driven luciferase
levels (Figure 4). This data suggests that DNp73 directly
contributes to the Nanog gene expression; thereby
DNp73 has greatly improved the efficiency of pluripo-
tent stem cells induction. Nanog is a key ES cell tran-
scription factor. Its over expression also might enhances
and improves other core ES cell transcription factors
such as OCT4 expression in previous studies [15,16].
Discussion
We found, for the first time, that additional expression
of DNp73 significantly increased human iPS cell genera-
tion by 12.6 folds, and also increased the kinetics, from
30 days to 21 days. These findings suggests that p73 is
an important factor involved in the generation of
human iPS cells. Furthermore, p73 has a unique dual
mechanism, whereby DNp73 acts as an oncogene and
increases iPS cell efficiency and kinetics, while TAp73
functions similarly to p53 in tumor suppression.
The strong impact of p53 on the iPS cell generation
was discovered previously [3] and Kawamura and group
[ 4 ]s h o w e dt h a tc e l l sd e f i c i e n ti nt h ep 5 3g e n ee x p r e s -
sion simplified the iPS cell generation requirement with
two factors: OCT4 and SOX2. In this study, we found
that DNp73 had a similar effect of enhancement on iPS
cell generation as p53. This system can also be applied
to detect whether C-terminal splicing proteins of p73 or
another p53 member, such as p63, are also important
for iPS cell generation or cell differentiation.
Grob et al. [13] found that DNp73 is capable of regu-
lating the function of both TAp73 and p53 and is also
strongly up-regulated by the TA isoforms and by p53,
creating a feedback loop that tightly regulates the func-
tion of TAp73 and p53. In this study, our data strongly
indicate that DNp73 expression decreases both p53 and
TAp73, leading to an increase in Nanog gene expres-
sion, which subsequently benefits somatic cell repro-
gramming and enhances iPS cell differentiation
resistance. The data also further suggests that DNp73
can be involved in tumorgenesis, at least teratoma-
tumorgenesis. More extensive analysis of the expression
pattern of DNp73 in other tumors and how the feed-
back loop is broken will require further studies.
Theunissen and Silva review [17] on Nanog expression
findings as follows: The loss of Nanog alleles are more
prone to differentiate but do not lose pluripotency per
se; Nanog is transiently required for the specification of
the naive pluripotent epiblast and is also essential to
finalize somatic cell reprogramming during induction of
Table 1 Comparison observation between teratoma derived from DNp73 overexpression iPSC and those derived from
control conditions of 4TF only iPSC
The iPSC for the teratoma derived Ratio of non- differentiated cells In 10 observed fields, the field numbers which
are all non-differentiated cells
4TF teratoma 0-30% 0
4TF plus DNp73 teratoma 30-100% 3
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on the naive pluripotent programme in mammalian
cells. However, Nanog expression also enforces tumor
genesis in some recent researches. Most recently, a
study by Grad I, et al. found that NANOG pre-induc-
tion followed by OCT3/4, SOX2, MYC, and KLF4
induction resulted in tumour-inducing phenotype [18].
Moon JH et al. [19] reported that Nanog-induced dedif-
ferentiation of p53-deficient mouse astrocytes into brain
cancer stem-like cells. Those results underline the
importance of a re-examination of the role of NANOG
during reprogramming. Our results show that DNp73
derived iPS cells might increase Nanog expression. Con-
sequently, the capacity of Nanog to resist differentiation
can be regarded as a recapitulation of specification of
somatic cell reprogramming, thus, resulting in a more
teratomacarcinoma-like cell due to Nanog over expres-
sion. The results further indicate that p53 family mem-
bers, including DNp73, might be key factors in
reprogramming and cancer development. Therefore, our
data provides a better understanding into tumour for-
mation and cancer stem cell transformation, at least
teratomatumorgenesis.
During iPS cell generation, global epigenetic modifica-
tions and chromatin changes, include histone modifica-
tions, DNA methylation, and chromatin remodeling
[20]. Patterson et al. [21] found that genes normally
unique to early embryos(LIN28A, LIN28B, DPPA4, and
others)were not fully silenced in human iPS cell deriva-
tives. LIN28 is an mRNA binding protein expressed in
embryonic stem cells (Patterson), and is one of the key
transcription factors for iPS cell generation [2]. Our
results showed that DNp73 might be involved in the
generation and in vitro differentiation of the iPS cells,
suggesting, a link among epigenetic modifications, iPS
cell gene expression and DNp73 in iPS cell generation
and early embryonic development. However, the impact
of DNp73 on epigenetic changes during iPS cell genera-
tion and derived cell lines has not been studied yet. A
rapidly accumulating body of evidence suggests that
there are important epigenetic differences between these
two cell types, which seem to influence their tumori-
genicity [22]. Therefore further studies on these epige-
netic modifications will be very interesting.
With small molecules, we developed an efficient set of
human-induced pluripotent stem cell(iPSC) methods
that improve iPSC generation by over 200-fold and cut
iPSC formation time in half [23]. Our results show TGF
beta, MEK, WNT and ROCK signaling pathway inhibi-
tion or interference might strongly impact iPS cell gen-
eration efficiency and kinetics [24]. Whether one or
more of these pathways are shared with DNp73 needs
further investigation.
Should iPS cells be applied to clinical application for
effective treatment of human diseases? The most suspi-
cious concerns are that iPS cells might be cancer prone.
More and more data suggests that iPS cells are very
similar to human tumor cells in the epigenetics as well
as genetic mutation accumulated during the generation
process. Hong et al. study found that some p53 inactiva-
tion in iPS cells produced tumors [3]. Genetic safety is
very critical for regenerative medicine. Further studies
might be necessary to decipher whether the over
expressed DNp73 is involved in the tumorigenesis, and
h o wp 7 3f u n c t i o n si nt h en o r m a li P Sc e l l s ?I ti sn o t
clear whether the p53 family members are a foe or
friend in iPS cell generation and clinical application [23].
Conclusions
DNp73 significantly increases human iPSC generation,
and also increases the kinetics. Therefore, other p53
family members, such as DNp73, are also involved in
human iPSC generation. Although the human iPS cell
generated with extra expression of DNp73 could differ-
entiate into some cell lines under certain conditions,
these cells were more resistant to in vitro and in vivo
differentiation cues.
Many other related questions, such as other p53
family members, the splicing variations, iPS cell genera-
tion efficiency mechanisms, related epigenetics and their
interactions need to be studied.
Methods
Cell culture
Human fibroblasts BJ (neonatal foreskin) were pur-
chased from American Typical Culture Center. Cell cul-
ture media reagents were from Invitrogen Corporation.
Figure 4 DNp73 over expression dramatically increases Nanog
promoter driven luciferase gene expression level. While, on the
contrary, p53 and TAp73 over expression significantly suppress
Nanog promoter driven luciferase gene expression. The transfection
construct amounts were applied at 10 ng or 500 ng per well of 24
well plates respectively. The p53 vector was served as positive
control and the results were compared to treatment with vector
only. Error bars: s.d. n = 3 independent experiments.
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FBS, 1× MEM Non-Essential amino acid, 1× glutamax,
10 mM Hepes and 0.11 mM 2-mercaptoethanol, with/
without 1× Penicillin/streptomycin. The cell was pas-
saged 1:3-5 using 0.05% (1×) trypsin-EDTA, and re-
seeded on gelatin coated plates.
Plasmids
The pMXs vector containing the human cDNAs for
OCT4 (POU5F1), SOX2, c-MYC (MYC) and KLF4,
described before [1], and were obtained from Addgene.
DNp73 was PCR amplified from human ES cell total
cDNA and inserted into pMXs. Mouse Slc7a1 ORF was
cloned into pWPXLD (Addgene), as described pre-
viously [1].
The retroviral infection and iPS cell generation
Lentiviruse carrying Slc7a1 was produced as described
before [1,8]. To improve infection efficiency, we per-
formed triplicates of the transduction on the parental
human fibroblast and checked the cells by infection with
GFP expression retrovirus. A transduction was deter-
mined to be good if over 60% of the GFP expression
cells produced the green fluorescence at day 3 after
infection with the GFP virus.
For retrovirus production, PLAT-E packaging cells
were plated at 1 × 106 cells per well in a 6-well plate.
After 24 h, the cells were transfected with OCT4
(POU5F1), SOX2, KLF4, cMYC as well as DNp73. The
vectors were transfected by using Fugene 6 transfection
reagent (Roche) according to manufacturer’si n s t r u c -
tions. Twentyfour hours after transfection, the medium
was replaced with fresh medium without antibiotics, and
the plate was transferred to 32°C for retrovirus produc-
tion. The viruses were collected at 48 h and 72 h and
filtered with 0.45 um filter before infection of human
fibroblast.
The Slc7a1-expressing human fibroblast cells were
seeded at 1 × 105 cells per well in a 6 well plate on day
1. On day 2, 0.25 ml of each retroviral supernatant was
added - 13 - to the cells and mixed with 1 ml fresh
medium (without antibiotics) in the presence of 6 ug/ml
polybrene. A second round of transduction was done on
day 3. Then, cells were infected with a mixture of fil-
tered virus, fresh medium and polybrene again.
Infection efficiency was estimated by fluorescence
microscopy on cells transduced in parallel with GFP or
RFP gene-carrying retroviruses.
Seven days after initial transduction, fibroblasts were
harvested by trypsinization and re-plated at 1 × 104
cells per well of a 6-well plate coated with matrigel
(1:50 dilution; BD Biosciences). Comparison was carry-
ing out at 4 TF only and 4TF plus DNp73. The media
was changed every 2 to 3 days depending on the cell
density. The plates were then, either fixed and stained
for ALP activity, or stained for protein markers, or the
cultures were continued, and the ES markers were
checked at day 14, 21 and 30.
Alkaline phosphatase (ALP) staining
ALP staining was performed using ALP detection kit
(Sigma) according to manufacturer’s instructions.
Immunocytochemistry staining
For immunocytochemistry, cells were fixed in 4% paraf-
ormaldehyde (10 min, room temperature), washed twice
with phosphate buffer saline (PBS), blocked with PBS
plus 5% normal donkey serum (Chemicon, or 2% BSA)
a n d0 . 1 %T r i t o n X - 1 0 0( 1 5m i n ,r o o mt e m p e r a t u r e )a n d
then treated with primary antibodies overnight at 4°c.
The primary antibodies used were antibodies to
NANOG(Chemicon; 1:1,000); to OCT4 (Santa Cruz Bio-
tech; 1:200), to SSEA 4 (Chemicon; 1:500), to Tra-1-81
(monoclonal antibody (mAb) Chemicon; 1:500), Beta III
Tubulin (Covance Research Products Inc; 1:1000), to
PDX 1(1:500) and to Brachyury (R&D; 1:500).
The cells were washed twice with PBS and then treated
with secondary antibodies for 1 h at room temperature.
T h es e c o n d a r ya n t i b o d i e su s e dw e r eA l e x af l u o r4 8 8
labeled donkey anti-rabbit or anti-mouse IgG (Invitrogen;
1:1,000) and Alexa fluor 555 labeled donkey anti-rabbit
or anti-mouse IgG(Invitrogen; 1:1,000). Nuclei were
stained with 0.5 ug/ml DAPI(Sigma). Images were cap-
tured using a Nikon Eclipse TE2000-U/X-cite 120 EXFO
microscope with a photometric camera.
In vitro differentiation and teratoma assay
Generation of embryoid bodies and in vitro differentia-
tion were performed as described above. For the tera-
toma assay, 3 to 5 million cells were injected under the
kidney capsule of severe combined immunodeficient
(SCID) mice. The animals used in this research were
approved by the Fujian Agriculture and Forestry Univer-
sity Animal Research Committee.
Real time-PCR
Total RNA was extracted from cells using RNAeasy
minikit(Qiagen). cDNAs were synthesized according to
product instructions using superscript III first strand
synthesis kit (Invitrogen). PCR cycles using respective
primers were performed. The sequences of the primers
are described in previous research papers [1,8].
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